On Tuesday, Bicara Therapeutics Inc (NASDAQ: BCAX) opened higher 9.58% from the last session, before settling in for the closing price of $11.48. Price fluctuations for BCAX have ranged from $7.80 to $28.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 42.88% at the time writing. With a float of $32.77 million, this company’s outstanding shares have now reached $54.53 million.
In an organization with 55 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Bicara Therapeutics Inc (BCAX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Bicara Therapeutics Inc is 39.92%, while institutional ownership is 62.30%. The most recent insider transaction that took place on Mar 14 ’25, was worth 1,021,211. In this transaction Chief Legal Officer of this company sold 79,146 shares at a rate of $12.90, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 14 ’25, when Company’s Officer proposed sale 79,146 for $13.35, making the entire transaction worth $1,056,599.
Bicara Therapeutics Inc (BCAX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 42.88% per share during the next fiscal year.
Bicara Therapeutics Inc (NASDAQ: BCAX) Trading Performance Indicators
Check out the current performance indicators for Bicara Therapeutics Inc (BCAX). In the past quarter, the stock posted a quick ratio of 24.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.54 in the next quarter and is forecasted to reach -2.65 in one year’s time.
Technical Analysis of Bicara Therapeutics Inc (BCAX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.19 million. That was better than the volume of 0.66 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 86.24%. Additionally, its Average True Range was 1.45.
During the past 100 days, Bicara Therapeutics Inc’s (BCAX) raw stochastic average was set at 53.83%, which indicates a significant decrease from 60.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 237.47% in the past 14 days, which was higher than the 119.57% volatility it showed in the past 100 days.
